Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection

Toshihiro Nishizawa, Hidekazu Suzuki, Ai Fujimoto, Hiroto Kinoshita, Shuntaro Yoshida, Yoshihiro Isomura, Akira Toyoshima, Takanori Kanai, Naohisa Yahagi, Osamu Toyoshima

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The effects of patient age on the efficacy of eradication treatment for Helicobacter pylori (H. pylori) remain unclear. The present study aimed to determine whether age affects eradication therapy involving vonoprazan, a novel potassium-competitive acid blocker (PCAB). We reviewed the cases of 3,261 patients who were administered first-line and second-line H. pylori eradication therapy at Toyoshima Endoscopy Clinic. The first-line treatment was clarithromycin and amoxicillin combined with a proton pump inhibitor (PPI) or a PCAB. The second-line treatment was metronidazole and amoxicillin combined with a PPI or PCAB. The patients were divided into a young to middle-aged group (age ≤50 years) and an older group (age >50 years) as well as into PPI and PCAB groups. The PPI-clarithromycin-amoxicillin regimen demonstrated a significantly lower H. pylori eradication rate than the PCAB-clarithromycin-amoxicillin regimen (p<0.001). With the PPI-clarithromycin-amoxicillin regimen, the eradication rate in the young to middle-aged group was significantly lower than that in the older group (p<0.001). Lastly, age had no impact on the eradication rate of PCAB-based therapy or metronidazole-based therapy. In conclusion, with clarithromycin-based triple therapy, PCAB is a better choice of antisecretory agent compared to PPIs, especially in young to middle-aged patients.

Original languageEnglish
Pages (from-to)208-210
Number of pages3
JournalJournal of Clinical Biochemistry and Nutrition
Volume60
Issue number3
DOIs
Publication statusPublished - 2017 May 1

Fingerprint

Helicobacter Infections
Helicobacter pylori
Clarithromycin
Potassium
Proton Pump Inhibitors
Amoxicillin
Acids
Metronidazole
Therapeutics
Age Groups
Endoscopy

Keywords

  • Age
  • Eradication
  • H. pylori
  • Proton pump inhibitor
  • Vonoprazan

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Clinical Biochemistry

Cite this

Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection. / Nishizawa, Toshihiro; Suzuki, Hidekazu; Fujimoto, Ai; Kinoshita, Hiroto; Yoshida, Shuntaro; Isomura, Yoshihiro; Toyoshima, Akira; Kanai, Takanori; Yahagi, Naohisa; Toyoshima, Osamu.

In: Journal of Clinical Biochemistry and Nutrition, Vol. 60, No. 3, 01.05.2017, p. 208-210.

Research output: Contribution to journalArticle

Nishizawa, Toshihiro ; Suzuki, Hidekazu ; Fujimoto, Ai ; Kinoshita, Hiroto ; Yoshida, Shuntaro ; Isomura, Yoshihiro ; Toyoshima, Akira ; Kanai, Takanori ; Yahagi, Naohisa ; Toyoshima, Osamu. / Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection. In: Journal of Clinical Biochemistry and Nutrition. 2017 ; Vol. 60, No. 3. pp. 208-210.
@article{b6fe44de9f4943bdbbe089f87963f81c,
title = "Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection",
abstract = "The effects of patient age on the efficacy of eradication treatment for Helicobacter pylori (H. pylori) remain unclear. The present study aimed to determine whether age affects eradication therapy involving vonoprazan, a novel potassium-competitive acid blocker (PCAB). We reviewed the cases of 3,261 patients who were administered first-line and second-line H. pylori eradication therapy at Toyoshima Endoscopy Clinic. The first-line treatment was clarithromycin and amoxicillin combined with a proton pump inhibitor (PPI) or a PCAB. The second-line treatment was metronidazole and amoxicillin combined with a PPI or PCAB. The patients were divided into a young to middle-aged group (age ≤50 years) and an older group (age >50 years) as well as into PPI and PCAB groups. The PPI-clarithromycin-amoxicillin regimen demonstrated a significantly lower H. pylori eradication rate than the PCAB-clarithromycin-amoxicillin regimen (p<0.001). With the PPI-clarithromycin-amoxicillin regimen, the eradication rate in the young to middle-aged group was significantly lower than that in the older group (p<0.001). Lastly, age had no impact on the eradication rate of PCAB-based therapy or metronidazole-based therapy. In conclusion, with clarithromycin-based triple therapy, PCAB is a better choice of antisecretory agent compared to PPIs, especially in young to middle-aged patients.",
keywords = "Age, Eradication, H. pylori, Proton pump inhibitor, Vonoprazan",
author = "Toshihiro Nishizawa and Hidekazu Suzuki and Ai Fujimoto and Hiroto Kinoshita and Shuntaro Yoshida and Yoshihiro Isomura and Akira Toyoshima and Takanori Kanai and Naohisa Yahagi and Osamu Toyoshima",
year = "2017",
month = "5",
day = "1",
doi = "10.3164/jcbn.16-86",
language = "English",
volume = "60",
pages = "208--210",
journal = "Journal of Clinical Biochemistry and Nutrition",
issn = "0912-0009",
publisher = "The Society for Free Radical Research Japan",
number = "3",

}

TY - JOUR

T1 - Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection

AU - Nishizawa, Toshihiro

AU - Suzuki, Hidekazu

AU - Fujimoto, Ai

AU - Kinoshita, Hiroto

AU - Yoshida, Shuntaro

AU - Isomura, Yoshihiro

AU - Toyoshima, Akira

AU - Kanai, Takanori

AU - Yahagi, Naohisa

AU - Toyoshima, Osamu

PY - 2017/5/1

Y1 - 2017/5/1

N2 - The effects of patient age on the efficacy of eradication treatment for Helicobacter pylori (H. pylori) remain unclear. The present study aimed to determine whether age affects eradication therapy involving vonoprazan, a novel potassium-competitive acid blocker (PCAB). We reviewed the cases of 3,261 patients who were administered first-line and second-line H. pylori eradication therapy at Toyoshima Endoscopy Clinic. The first-line treatment was clarithromycin and amoxicillin combined with a proton pump inhibitor (PPI) or a PCAB. The second-line treatment was metronidazole and amoxicillin combined with a PPI or PCAB. The patients were divided into a young to middle-aged group (age ≤50 years) and an older group (age >50 years) as well as into PPI and PCAB groups. The PPI-clarithromycin-amoxicillin regimen demonstrated a significantly lower H. pylori eradication rate than the PCAB-clarithromycin-amoxicillin regimen (p<0.001). With the PPI-clarithromycin-amoxicillin regimen, the eradication rate in the young to middle-aged group was significantly lower than that in the older group (p<0.001). Lastly, age had no impact on the eradication rate of PCAB-based therapy or metronidazole-based therapy. In conclusion, with clarithromycin-based triple therapy, PCAB is a better choice of antisecretory agent compared to PPIs, especially in young to middle-aged patients.

AB - The effects of patient age on the efficacy of eradication treatment for Helicobacter pylori (H. pylori) remain unclear. The present study aimed to determine whether age affects eradication therapy involving vonoprazan, a novel potassium-competitive acid blocker (PCAB). We reviewed the cases of 3,261 patients who were administered first-line and second-line H. pylori eradication therapy at Toyoshima Endoscopy Clinic. The first-line treatment was clarithromycin and amoxicillin combined with a proton pump inhibitor (PPI) or a PCAB. The second-line treatment was metronidazole and amoxicillin combined with a PPI or PCAB. The patients were divided into a young to middle-aged group (age ≤50 years) and an older group (age >50 years) as well as into PPI and PCAB groups. The PPI-clarithromycin-amoxicillin regimen demonstrated a significantly lower H. pylori eradication rate than the PCAB-clarithromycin-amoxicillin regimen (p<0.001). With the PPI-clarithromycin-amoxicillin regimen, the eradication rate in the young to middle-aged group was significantly lower than that in the older group (p<0.001). Lastly, age had no impact on the eradication rate of PCAB-based therapy or metronidazole-based therapy. In conclusion, with clarithromycin-based triple therapy, PCAB is a better choice of antisecretory agent compared to PPIs, especially in young to middle-aged patients.

KW - Age

KW - Eradication

KW - H. pylori

KW - Proton pump inhibitor

KW - Vonoprazan

UR - http://www.scopus.com/inward/record.url?scp=85019705645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019705645&partnerID=8YFLogxK

U2 - 10.3164/jcbn.16-86

DO - 10.3164/jcbn.16-86

M3 - Article

AN - SCOPUS:85019705645

VL - 60

SP - 208

EP - 210

JO - Journal of Clinical Biochemistry and Nutrition

JF - Journal of Clinical Biochemistry and Nutrition

SN - 0912-0009

IS - 3

ER -